Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    CREST-E
Previous Study | Return to List | Next Study

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) (CREST-E)

This study has been terminated.
(Results of an interim analysis showed that it was unlikely that creatine was effective in slowing loss of function in early symptomatic Huntington's Disease.)
University of Rochester
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Steven M. Hersch, Massachusetts General Hospital Identifier:
First received: July 8, 2008
Last updated: February 10, 2016
Last verified: February 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2015
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 10, 2016